Press Release 18 Dec 2013

‘Subject to planning approval and permitting, the company will invest $300 million and create 300 high-skill jobs by 2016’

Limerick, 18th December 2013: Minister Richard Bruton, Minister for Jobs, Enterprise and Innovation has announced that Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is to apply for planning permission to establish a state-of-the art, biopharmaceutical production facility within a 11.88 hectare site, previously owned by Dell in the Raheen Business Park, Limerick. This project supported by the Department of Jobs through IDA Ireland, which has worked with the company for the past four years to attract it to invest in Ireland, has also been welcomed by Minister Noonan to Limerick.

Subject to planning approval from the local authority, the company expects to employ up to 300 people by the end of 2016, including scientists, engineers, technicians and administrative personnel. The proposed $300 million investment programme will involve the major refurbishment of existing buildings on the site (vacant since 2009) and the construction of a quality control laboratory, which will transform the site into a world-class biopharmaceutical campus. Subject to a successful permit, construction and refurbishment is anticipated to begin in 2014 for a two-year period, generating up to 600 temporary construction jobs for local contractors.

“Regeneron is one of the largest and fastest-growing biopharmaceutical companies in the United States," said Daniel Van Plew, Regeneron’s Senior VP & GM of Industrial Operations and Product Supply. "Pending planning approval, Limerick will become our second industrial production site, expanding our manufacturing capacity into Europe and facilitating the delivery of a growing supply of medicines for patients worldwide.”

Van Plew continued, “Ireland has a highly educated work force and a strong biopharma industry while the Irish Government has an unparalleled commitment to education and training for pharmaceutical manufacturing, quality assurance, quality control and supply logistics. We hope to work with the National Institute for Bioprocessing Research & Training (NIBRT) and are already in discussions with the universities and colleges in Limerick about future possibilities. We see Limerick as a good place to do business – the area has excellent educational institutes, a strong community spirit and a solid transport infrastructure. We are grateful to IDA Ireland for its support in helping us secure this facility and we look forward to playing an active role in Ireland’s biopharma sector and building strong relationships with key stakeholders.”

Welcoming the announcement, the Minister for Jobs, Enterprise and Innovation, Richard Bruton, TD said, “Sustaining and building on Ireland’s strong track record in pharmaceuticals is a key objective of our Action Plan for Jobs. In recent years despite global difficulties employment in the sector in Ireland has been growing. Today’s announcement that subject to planning permission, Regeneron plans to establish a major operation in Limerick with the creation of 300 jobs is another significant jobs boost for the sector and for the city. With Regeneron confirming its intention to establish operations in Ireland, IDA Ireland with the support of my Department has now secured nine of the top ten global BioPharma companies to locate major facilities in Ireland. I am determined to build on this and secure further announcements like this over the coming months.”

The Minister for Finance, Michael Noonan TD said, “The Regeneron investment in Limerick is great news for Limerick and for the local economy. The company is making a major commitment to Ireland by refurbishing an unoccupied facility in Raheen Business Park, creating a substantial number of both construction and long-term permanent jobs. I welcome Regeneron to Limerick and offer the company my enthusiastic support. I look forward to meeting Regeneron senior executives when I travel to New York in January and discussing their plans for Limerick.”

Commenting on the announcement, Barry O’Leary, CEO of IDA Ireland said, “Regeneron’s decision to locate this strategically important investment here is a clear endorsement of Ireland’s recognised strengths in the pharma and BioPharma field. BioPharma companies like Regeneron are currently developing and manufacturing the “next generation” of medicines. This activity represents the cutting edge of innovative drug development and requires skilled, highly qualified staff. This announcement is a reflection of the attractiveness of Limerick and the Mid-West region to leading global investors. Regeneron joins a thriving life science sector in the region which offers excellent employment opportunities and makes a substantial contribution to the local economy. IDA Ireland took a strategic decision to target the biopharma sector in recent years.”

Ends.

For ref: IDA Ireland - Kevin Sammon 01-6034000 / 087-6188564

DJEI: Conor Quinn, Tel: 01- 631 2200, 087-3743783.

Peter Dworkin / VP Corporate Communications - Regeneron Pharmaceuticals, 777 Old Saw Mill River Road Tarrytown, NY 10591. Tel. 914-847-7640

Regeneron: (Ireland) C/o: Pat Keating, Keating & Associates. Tel. 087-2541757 – pat@keating.ie

Notes:

Recruitment:
Recruitment will be gradual for senior management and specialist staff initially building gradually from 2014 to 2016. Interested parties can view details of available positions for Regeneron in Limerick on: www.regeneron.com. Recruitment specialists, CPL (regeneron@cpl.ie) are currently engaged in some early stage recruitment.

Contact:
In the short-term, supplier enquiries or submissions relating to the possible provision of materials or services should be mailed to; Regeneron, PO Box 12491, Dublin 2, or emailed to; limerick@regeneron.com from where they will be appropriately processed or held on file for consideration.

About Regeneron Pharmaceuticals, Inc.
Regeneron is a leading science-based biopharmaceutical company based in Tarrytown, New York, USA, that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. Regeneron markets medicines for eye diseases, colorectal cancer, and a rare inflammatory condition and has product candidates in development in other areas of high unmet medical need, including hypercholesterolemia, oncology, rheumatoid arthritis, asthma, and atopic dermatitis. For additional information about the company, please visit www.regeneron.com.

Please find link to Regeneron’s Community Newsletter here

Contact us

Contact IDA Ireland

You'll find us responsive to your needs, proactive, professional and willing to go the extra mile.

Contact IDA Ireland

International Offices

We have 28 Offices worldwide helping support companies expand their operations in Ireland.

Find your nearest office